Clinical study for monitoring of therapy effect on breast cancer using 18F-fluoromisonidazole PET/CT

Clinical study for monitoring of therapy effect on breast cancer using 18F-fluoromisonidazole PET/CT - Monitoring of therapy effect on breast cancer using 18F-FMISO PET/CT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006802

Enrollment

100

Registered

2011-12-01

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

PET/CT imaging 2 hrs after administration of F-18-fluoromisonidazole (FMISO) ( 7.4MBq/kg ) at 3 time points of pretherapy, 2-4 cycles after chemotherapy and posttherapy ( presurgery ).

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with breast cancer who are eligible for surgical treatment. 2) Patients with breast cancer who are eligible for surgical treatment after presurgical treatment ( chmotherapy and/or hormone therapy ). 3) Patients who are consent to participate in this study

Exclusion criteria

Exclusion criteria: 1) Pregnant female or female having possibility of pregnancy 2) Patients ineligible for participating in this study because of other reasons

Design outcomes

Primary

Measure	Time frame
Relation between the shrinkage and the FMISO uptake in the breast cancer after 2-4 cycles of chemotherapy and after completion of therapy.	—

Secondary

Measure	Time frame
Relation between the prognosis and the FMISO uptake in the breast cancer after 2-4 cycles of chemotherapy and after completion of therapy.	—

Countries

Japan

Contacts

Public ContactIchiei Kuji

Saitama International Medical Center, Saitama Medical University Clinical test assistant center

chikens@saitama-med.ac.jp042-984-4523

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026